Moreover, the ICOS/ICOS-L dyad may even play a role in anti-CTLA4 monoclonal antibody (mAb) anti-tumor activity, which results in an expansion of ICOS+ effector T cells, while its effect is significantly decreased in ICOS-/- mice [13]. Here, ICOSLG is linked to neoplasm.